Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient ... Read more
Australian scientists have created a promising new vaccine candidate against cancers that express the Wilms’ tumor 1 (WT1) gene. These include cancers of the blood, like acute myeloid leukemia (AML), ... Read more
Pfizer announced that the European Commission has approved Daurismo (glasdegib) in combination with low-dose cytarabine to treat newly diagnosed acute myeloid leukemia (AML) among adults who are not candidates ... Read more
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for ... Read more
Despite disruptions from the COVID-19 pandemic, Moleculin Biotech is aiming to expand the number of sites for clinical trials of its annamycin chemotherapy for the treatment of acute myeloid ... Read more
The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis ... Read more